Healthcare Experience

Brand Institute Healthcare Share of Market


Our Healthcare experience includes 609 clients, with 2421 partnered brands and 503 USAN/INN names. Below is our extensive portfolio, feel free to filter by clients, brands, category or USAN/INN Names.   ||  Click Here for Consumer/B2B Experience



CLIENTS BRANDS CATEGORY
4SC resminostat Oncology
ABBOTT LABORATORIES enavatuzumab Oncology
ABBVIE navitoclax Oncology
ABBVIE elotuzumab Oncology
ABBVIE linifanib Oncology
ABBVIE veliparib Oncology
ABBVIE ilorasertib Oncology
ABBVIE venetoclax Oncology
ABBVIE depatuxizumab Oncology
ABBVIE depatuxizumab mafdotin Oncology
ABBVIE telisotuzumab Oncology
ABBVIE telisotuzumab vedotin Oncology
ACERTA PHARMA acalabrutinib Oncology
ACETYLON ricolinostat Oncology
ADVAXIS axalimogene filolisbac Oncology
AGIOS enasidenib Oncology
AGIOS ivosidenib Oncology
AMGEN bevacizumab beta Oncology
AMGEN sitravatinib Oncology
AMGEN KYPROLIS * Oncology
AMGEN BLINCYTO * Oncology
AMGEN XGEVA Oncology
AMGEN trebananib Oncology
AMGEN oprozomib Oncology
APOTEX docetaxel Oncology
ARIAD ICLUSIG Oncology
ARIAD ponatinib Oncology
ARIAD ponatinib hydrochloride Oncology
ASTELLAS XTANDI Oncology
ASTEX guadecitabine Oncology
ASTRAZENECA savolitinib Oncology
ASTRAZENECA CASODEX OD
(カソデックスOD)
Oncology
ASTRAZENECA TAGRISSO * Oncology
ASTRAZENECA acalabrutinib Oncology
ASTRAZENECA selumetinib sulfate Oncology
ASTRAZENECA CAPRELSA Oncology
ASTRAZENECA bicalutamide Oncology
ASTRAZENECA CASODEX Oncology
ASTRAZENECA FASLODEX * Oncology
ASTRAZENECA IRESSA * Oncology
ASTRAZENECA selumetinib Oncology
ASTRAZENECA ZOLADEX Oncology
ATRIX LABORATORIES ELIGARD * Oncology
BASILEA PHARMACEUTICALS lisavanbulin Oncology
BAYER aprutumab Oncology
BAYER aprutumab ixadotin Oncology
BAYER darolutamide Oncology
BAYER NEXAVAR * Oncology
BAYER sorafenib Oncology
BAYER VIADUR Oncology
BAYER radretumab Oncology
BAYER XOFIGO Oncology
BAYER roniciclib Oncology
BAYER XOFIGO (RADIUM RA 223 DICHLORIDE) Oncology
BAYER refametinib Oncology
BAYER copanlisib Oncology
BELLICUM PHARMACEUTICALS rimiducid Oncology
BIO-PATH HOLDINGS prexigebersen Oncology
BIOGEN IDEC RITUXAN Oncology
BIOMARIN talazoparib Oncology
BIOMED VALLEY ulixertinib Oncology
BIONUMERIK PHARMACEUTICALS TAVOCEPT Oncology
BIPAR iniparib Oncology
BLAZE BIOSCIENCE tozuleristide Oncology
BOEHRINGER INGELHEIM GILOTRIF Oncology
BRISTOL-MYERS SQUIBB TANESPIMYCIN Oncology
Bristol-Myers Squibb alvespimycin Oncology
Bristol-Myers Squibb alvespimycin hydrochloride Oncology
CANTEX PHARMACEUTICALS dociparstat Oncology
Cascadian Therapeutics tucatinib Oncology
Cascadian Therapeutics sonolisib Oncology
CASI PHARMACEUTICALS PANZEM Oncology
CASI PHARMACEUTICALS PROMUNE Oncology
CELGENE pomalidomide Oncology
CELGENE amrubicin hydrochloride Oncology
CELGENE mocetinostat Oncology
CELGENE mocetinostat dihydrobromide Oncology
CELGENE VIDAZA Oncology
CELGENE ISTODAX * Oncology
CELLTRION HEALTHCARE TRUXIMA Oncology
CELLTRION HEALTHCARE HERZUMA Oncology
CEPHALON SYNRIBO * Oncology
CEPHALON TREANDA * Oncology
CEPHALON omacetaxine mepesuccinate Oncology
CEPTARIS THERAPEUTICS VALCHLOR * Oncology
CHUGAI PHARMA ALECENSA * Oncology
CLOVIS rociletinib Oncology
DAIICHI-SANKYO pexidartinib Oncology
DAIICHI-SANKYO patritumab Oncology
DAIICHI-SANKYO tivantinib Oncology
DENDREON PROVENGE Oncology
DENDREON lapuleucel-t Oncology
DENDREON sipuleucel-t Oncology
EAGLE PHARMACEUTICALS BENDEKA * Oncology
EISAI LENVIMA Oncology
EISAI KISPLYX Oncology
EISAI DACOGEN Oncology
EISAI HALAVEN Oncology
ELI LILLY PORTRAZZA Oncology
EMD SERONO evobrutinib Oncology
EPIZYME tazemetostat Oncology
EPIZYME pinometostat Oncology
ERIMOS PHARMACEUTICALS terameprocol Oncology
EXELIXIS cabozantinib Oncology
FIVE PRIME THERAPEUTICS cabiralizumab Oncology
GENENTECH TECENTRIQ * Oncology
GENENTECH atezolizumab Oncology
GENENTECH ALECENSA * Oncology
GENENTECH duligotuzumab Oncology
GENENTECH taselisib Oncology
GENENTECH cobimetinib Oncology
GENENTECH polatuzumab vedotin Oncology
GENENTECH pinatuzumab vedotin Oncology
GENENTECH ipatasertib Oncology
GENENTECH KADCYLA (カドサイラ) Oncology
GENENTECH GAZYVA * Oncology
GENENTECH PERJETA (パージェタ) * Oncology
GENENTECH RITUXAN Oncology
GENENTECH AVASTIN * Oncology
GENENTECH dulanermin Oncology
GENENTECH TARCEVA * Oncology
GENMAB ARZERRA (アーゼラ) Oncology
GENOMIC HEALTH GENOMIC PROSTATE SCORE (GPS) Oncology
GENTA GENASENSE Oncology
GERON paclitaxel trevatide Oncology
GILEAD acalisib Oncology
GILEAD entospletinib Oncology
GILEAD andecaliximab Oncology
GILEAD vesatolimod Oncology
GILEAD idelalisib Oncology
GILEAD simtuzumab Oncology
GILEAD tirabrutinib Oncology
GLAXOSMITHKLINE ARZERRA (アーゼラ) Oncology
GLAXOSMITHKLINE astuprotimut-r Oncology
GLAXOSMITHKLINE BEXXAR * Oncology
GLAXOSMITHKLINE CYTEFURAN Oncology
GLAXOSMITHKLINE REZONIC Oncology
GLAXOSMITHKLINE VOTRIENT * Oncology
GLAXOSMITHKLINE uprosertib Oncology
GLAXOSMITHKLINE omipalisib Oncology
GLAXOSMITHKLINE zastumotide Oncology
GLAXOSMITHKLINE TAFINLAR * Oncology
GLAXOSMITHKLINE MEKINIST * Oncology
HALOZYME THERAPEUTICS pegvorhyaluronidase alfa Oncology
HANMI PHARMACEUTICALS poseltinib Oncology
HANMI PHARMACEUTICALS olmutinib Oncology
HELSINN HEALTHCARE AMIXEA Oncology
HELSINN HEALTHCARE RESSURO Oncology
IGNYTA entrectinib Oncology
IMCLONE SYSTEMS PORTRAZZA Oncology
IMMUNOGEN mirvetuximab soravtansine Oncology
IMMUNOGEN laprituximab Oncology
IMMUNOGEN laprituximab emtansine Oncology
IMMUNOGEN naratuximab emtansine Oncology
IMMUNOGEN cantuzumab ravtansine Oncology
IMMUNOGEN lorvotuzumab mertansine Oncology
INNOCRIN PHARMACEUTICALS seviteronel Oncology
INSPYR Therapeutics mipsagargin Oncology
INTREXON veledimex Oncology
INTROGEN THERAPEUTICS ADVEXIN * Oncology
IPR PHARMS CAPRELSA Oncology
ISOTECHNIKA terameprocol Oncology
JANSSEN YONDELIS * Oncology
JANSSEN ZYTIGA * Oncology
JANSSEN daratumumab Oncology
JANSSEN SYLVANT Oncology
JANSSEN DARZALEX * Oncology
JANSSEN DARZALEX Oncology
JANSSEN seltorexant Oncology
JAZZ PHARMACEUTICALS pegcrisantaspase Oncology
JENNEREX pexastimogene devacirepvec Oncology
JOHNSON & JOHNSON quisinostat Oncology
JOHNSON & JOHNSON intetumumab Oncology
JOHNSON & JOHNSON serdemetan Oncology
JOHNSON & JOHNSON siltuximab Oncology
JOHNSON & JOHNSON talmapimod Oncology
JOHNSON & JOHNSON carlumab Oncology
KARYOPHARM selinexor Oncology
KYOWA HAKKO KIRIN POTELIGEO Oncology
LIGAND PHARMACEUTICALS ONTAK Oncology
LIGAND PHARMACEUTICALS TARGRETIN * Oncology
LOXO ONCOLOGY larotrectinib Oncology
LUNDBECK INC. TREANDA * Oncology
LUNDBECK INC. ingenol disoxate Oncology
LUNDBECK INC. TRISENOX * Oncology
MAST THERAPEUTICS folitixorin Oncology
MAST THERAPEUTICS folitixorin calcium Oncology
MEDIMMUNE blinatumomab Oncology
MEDIMMUNE etaracizumab Oncology
MEDIMMUNE moxetumomab pasudotox Oncology
MEDIVATION enzalutamide Oncology
MEDIVATION XTANDI * Oncology
MERCK & CO. KEYTRUDA Oncology
MERCK & CO. pembrolizumab Oncology
MERCK & CO. SYLATRON Oncology
MERCK & CO. TEMODAR * Oncology
MERCK & CO. ZOLINZA Oncology
MILLENNIUM PHARMACEUTICALS alisertib Oncology
MILLENNIUM PHARMACEUTICALS ixazomib Oncology
MILLENNIUM PHARMACEUTICALS orteronel Oncology
MILLENNIUM PHARMACEUTICALS NINLARO Oncology
MILLENNIUM PHARMACEUTICALS sapanisertib Oncology
MILLENNIUM PHARMACEUTICALS indusatumab Oncology
MILLENNIUM PHARMACEUTICALS indusatumab vedotin Oncology
MIRATI THERAPEUTICS glesatinib Oncology
MOLOGEN lefitolimod Oncology
MUNDIPHARMA tinostamustine Oncology
MYRIAD verubulin Oncology
NEKTAR etirinotecan pegol Oncology
NEKTAR etirinotecan pegol tetrahydrochloride Oncology
NEKTAR etirinotecan pegol tetratriflutate Oncology
NEOGENIX ONCOLOGY ensituximab Oncology
NIPPON KAYAKU firtecan peglumer Oncology
NOVARTIS ZYKADIA * Oncology
NOVARTIS ODOMZO Oncology
NOVARTIS FARYDAK * Oncology
NOVARTIS JAKAVI Oncology
NOVARTIS VOTUBIA Oncology
NOVARTIS AFINITOR Oncology
NOVARTIS AMDRAY * Oncology
NOVARTIS lucatumumab Oncology
NOVARTIS TASIGNA Oncology
NOVARTIS ZOMETA * Oncology
NOVARTIS dovitinib Oncology
NOVARTIS dovitinib lactate Oncology
OCTAPHARMA AB satoreotide Oncology
OCTREOPHARM satoreotide trizoxetan Oncology
ONCOMED navicixizumab Oncology
ONCOMED brontictuzumab Oncology
ONCOMED vantictumab Oncology
ONCOMED tarextumab Oncology
ONCOMED ipafricept Oncology
ONCOMED demcizumab Oncology
ONCOMED rosmantuzumab Oncology
ONCOPEPTIDES melphalan flufenamide Oncology
ONCOTHERAPY SCIENCE latromotide Oncology
ONCOTHERAPY SCIENCE pradimotide Oncology
ONCOTHERAPY SCIENCE elpamotide Oncology
OSI PHARMACEUTICALS linsitinib Oncology
OSI PHARMACEUTICALS TARCEVA * Oncology
OXIGENE fosbretabulin Oncology
OXIGENE fosbretabulin disodium Oncology
OXIGENE fosbretabulin tromethamine Oncology
PENDOPHARM ZEULIDE DEPOT * Oncology
PFIZER IBRANCE Oncology
PFIZER agatolimod Oncology
PFIZER METARET Oncology
PFIZER SYNTHOKINE Oncology
PFIZER TRELSTAR Oncology
PFIZER gemtuzumab ozogamicin Oncology
PHARMACYCLICS abexinostat Oncology
PHARMACYCLICS ibrutinib Oncology
PHARMACYCLICS IMBRUVICA * Oncology
PORTOLA cerdulatinib Oncology
QLT USA ELIGARD Oncology
RADIUS HEALTH elacestrant Oncology
REGENERON PHARMACEUTICALS ZALTRAP Oncology
ROCHE KADCYLA (カドサイラ) Oncology
ROCHE GAZYVA * Oncology
ROCHE ALECENSARO * Oncology
ROCHE TARCEVA * Oncology
ROCHE XELODA Oncology
ROCHE imgatuzumab Oncology
SANOFI TAXOTERE Oncology
SANOFI ELIGARD Oncology
SANOFI ELITEK Oncology
SANOFI ELOXATIN Oncology
SANOFI NILANDRON Oncology
SANOFI PLENAXIS * Oncology
SANOFI isatuximab Oncology
SANOFI pilaralisib Oncology
SANOFI seribantumab Oncology
SANOFI voxtalisib Oncology
SANOFI ZALTRAP Oncology
SANOFI JEVTANA * Oncology
SANOFI fedratinib Oncology
SEATTLE GENETICS enfortumab vedotin Oncology
SEATTLE GENETICS denintuzumab mafodotin Oncology
SEATTLE GENETICS vadastuximab talirine Oncology
SEATTLE GENETICS vadastuximab Oncology
SEATTLE GENETICS ADCETRIS (アドセトリス) * Oncology
SEATTLE GENETICS vorsetuzumab mafodotin Oncology
SHIONOGI PHARMA asudemotide Oncology
SHIONOGI PHARMA trempamotide Oncology
SHIONOGI PHARMA alicdamotide Oncology
SHIONOGI PHARMA epertinib Oncology
SHIRE PHARMACEUTICALS imalumab Oncology
SIEMENS flortanidazole (18f) Oncology
SIEMENS flotegatide (18f) Oncology
SPECTRUM PHARMACEUTICALS MARQIBO Oncology
SPECTRUM PHARMACEUTICALS belinostat Oncology
SPECTRUM PHARMACEUTICALS FUSILEV Oncology
SPECTRUM PHARMACEUTICALS FOLOTYN Oncology
SPECTRUM PHARMACEUTICALS ZEVALIN Oncology
SPECTRUM PHARMACEUTICALS BRAKIVA Oncology
SPECTRUM PHARMACEUTICALS KYRBAX Oncology
STEMCENTRX rovalpituzumab Oncology
STEMCENTRX rovalpituzumab tesirine Oncology
SUNESIS PHARMACEUTICALS vosaroxin Oncology
SYNTA PHARMACEUTICALS elesclomol Oncology
SYNTA PHARMACEUTICALS rosabulin Oncology
TAIHO PHARMA TEYSUNO * Oncology
TAIHO PHARMA LONSURF Oncology
TAKEDA PHARMACEUTICALS NINLARO Oncology
TAKEDA PHARMACEUTICALS VELCADE Oncology
TAKEDA PHARMACEUTICALS serabelisib Oncology
TESARO belizatinib Oncology
TEVA PHARMACEUTICAL INDUSTRIES BENDEKA * Oncology
THRESHOLD PHARMACEUTICALS tarloxotinib bromide Oncology
TRACON PHARMACEUTICALS carotuximab Oncology
TYROGENEX vorolanib Oncology
UNITED THERAPEUTICS UNITUXIN Oncology
VION laromustine Oncology
XCOVERY ensartinib Oncology
YM BIOSCIENCES lexibulin Oncology
ZYMOGENETICS CERVATEC Oncology


* Denotes a comprehensive report of the safety regulatory research prepared by BI/DSI for submission of this name candidate to FDA and/or EMA, and/or Health Canada, and other Regulatory Agencies.

Back to top